Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 97Myelodysplastic Syndromes 73Precursor Cell Lymphoblastic Leukemia-Lymphoma 61Leukemia, Lymphocytic, Chronic, B-Cell 59Leukemia 55Lymphoma, Non-Hodgkin 45Lymphoma 43Leukemia, Myelogenous, Chronic, BCR-ABL Positive 43Multiple Myeloma 42Hodgkin Disease 38Hematologic Neoplasms 35Myeloproliferative Disorders 24Melanoma 22Lymphoma, Mantle-Cell 18Recurrence 17Lymphoma, Follicular 17Neoplasms 16Lymphoma, Large B-Cell, Diffuse 15Primary Myelofibrosis 14Lymphoma, B-Cell 14Burkitt Lymphoma 14Anemia, Refractory, with Excess of Blasts 14Lymphoma, B-Cell, Marginal Zone 13Leukemia, Myelomonocytic, Chronic 13Leukemia, Biphenotypic, Acute 13Graft vs Host Disease 13Hematologic Diseases 12Anemia, Aplastic 11Skin Neoplasms 10Ovarian Neoplasms 10

Interventions

Cyclophosphamide 3tumor necrosis factor-alpha, CNGRC fusion protein, human 2liposomal doxorubicin 2Paclitaxel 2Gemcitabine 2Doxorubicin 2Dexamethasone 2Cisplatin 2Carboplatin 2Bortezomib 2vandetanib 1umbralisib 1ublituximab 1regorafenib 1pomalidomide 1pembrolizumab 1nilotinib 1marizomib 1lutetium Lu 177 dotatate 1grapiprant 1fludarabine phosphate 1fludarabine 1durvalumab 1cemiplimab 1carotuximab 1axicabtagene ciloleucel 1avelumab 1Thioctic Acid 1Tamoxifen 1Receptors, Interleukin-6 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Disease Progression × fludarabine × Clear all
NCT04205838 2026-02-27

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
23 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡